{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003318","form_type":"8-K","ticker":"IBO","cik":"0001834105","company_name":"IMPACT BIOMEDICAL INC.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.851110+00:00","generated_at":"2026-06-06T20:46:38.182362+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Impact BioMedical amends $12.86M promissory note with DSS; extends maturity to 2030","bullets":["Funded principal balance increased to $12,859,328.60, including $1.23M in interest advances.","Maturity extended to September 30, 2030; repayment in 60 monthly payments starting February 2024.","Interest rate set at WSJ Prime + 0.50% (initially 9%); note is secured by blanket first lien on all assets.","DSS, Inc., the majority shareholder of Impact, is the lender; no advance features remain under the note.","Financial covenants require Impact to maintain positive net worth and limit additional indebtedness."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003318","json":"https://secwatch.observer/filing/0001493152-24-003318.json","markdown":"https://secwatch.observer/filing/0001493152-24-003318.md","text":"https://secwatch.observer/filing/0001493152-24-003318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/0001493152-24-003318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:46:38.182362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5eb5f5a2f76e8dba90a6e8cadced530355635441","claim":"IMPACT BIOMEDICAL INC. amended Amended Revolving Promissory Note dated March 1, 2023 with DSS, Inc. valued at Principal balance of $12,859,328.60; maturity extended to September 30, 2030; WSJ Prime + 0.50% floa (effective 2024-01-18).","evidence_excerpt":"Effective January 18, 2024, DSS, Inc., a New York corporation (\"DSS\") and Impact BioMedical, Inc., a Nevada corporation (\"Impact\") entered into an amendment to the revolving promissory note dated March 1, 2023 (the \"Original Note\"), whereby DSS loaned Impact an original amount of up to $12,000,000 (the \"Loan\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/0001493152-24-003318-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"DSS, Inc."},{"label":"Value","value":"Principal balance of $12,859,328.60; maturity extended to September 30, 2030; WSJ Prime + 0.50% floa"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}